RecruitingPhase 3NCT07503730

Early Use of Realgar-Indigo Naturalis Formula (RIF) Combined With All-trans Retinoic Acid (ATRA) for Treating Acute Promyelocytic Leukemia (APL).

Studying Acute promyelocytic leukemia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
First Affiliated Hospital Xi'an Jiaotong University
Intervention
ATRA(drug)
Enrollment
224 enrolled
Eligibility
18-80 years · All sexes
Timeline
20252028

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07503730 on ClinicalTrials.gov

Other trials for Acute promyelocytic leukemia

Additional recruiting or active studies for the same condition.

See all trials for Acute promyelocytic leukemia

← Back to all trials